Back to Search
Start Over
Tocilizumab Employment in the Treatment of Resistant Juvenile Idiopathic Arthritis Associated Uveitis.
- Source :
-
Ocular immunology and inflammation [Ocul Immunol Inflamm] 2021 Jan 02; Vol. 29 (1), pp. 14-20. Date of Electronic Publication: 2020 Oct 06. - Publication Year :
- 2021
-
Abstract
- Aim: To determine the efficacy and safety of intravenous tocilizumab in refractory juvenile idiopathic arthritis associated uveitis.<br />Patients and Methods: This was a retrospective observational case series. Patients with refractory juvenile idiopathic arthritis associated uveitis, who had received tocilizumab were included in this study.<br />Results: 8 patients (14 eyes) were included in this study. The average age of the patients at the first visit was 16.8 ± 11.2 years (7-40). The average duration of follow-up period after starting treatment was 28.6 ± 24.6 months (9-70). Intravenous tocilizumab infusions induced and maintained remission in 5 patients (8 eyes). Vasculitis was resolved within 8 months in all but one patient. The presence of papillitis before starting treatment was directly correlated with visual acuity improvement. No side effects were observed.<br />Conclusion: Intravenous tocilizumab infusion can be an effective and safe method of treatment to induce and maintain remission in resistant juvenile idiopathic arthritis associated uveitis.
Details
- Language :
- English
- ISSN :
- 1744-5078
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Ocular immunology and inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 33021415
- Full Text :
- https://doi.org/10.1080/09273948.2020.1817501